We are live on ! Find out more
ACRV icon

Acrivon Therapeutics
ACRV

48 hedge funds and large institutions have $109M invested in Acrivon Therapeutics in 2024 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 6

56% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 9

46% more capital invested

Capital invested by funds: $74.6M → $109M (+$34.4M)

14% more funds holding

Funds holding: 42 → 48 (+6)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.4% less ownership

Funds ownership: 69.11% → 68.7% (-0.4%)

Holders
48
Holders Change
+6
Holders Change %
+14.29%
% of All Funds
0.69%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
12
Increased
14
Reduced
9
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$827K
2
Renaissance Technologies
Renaissance Technologies
New York
+$476K
3
Millennium Management
Millennium Management
New York
+$443K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$249K
5
BBA
Baker Bros. Advisors
New York
+$245K

Top Sellers

Rank Fund Capital Flow
1
NMC
NEA Management Company
Maryland
-$1.29M
2
Federated Hermes
Federated Hermes
Pennsylvania
-$1.11M
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$227K
4
Morgan Stanley
Morgan Stanley
New York
-$158K
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$157K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$34.4M – – –
PA
2
Perceptive Advisors
New York
$21.5M – – –
Citadel Advisors
3
Citadel Advisors
Florida
$12M +$141K +30,368 +2%
SCV
4
Sands Capital Ventures
Virginia
$11.8M – – –
Wellington Management Group
5
Wellington Management Group
Massachusetts
$6.35M – – –
BlackRock
6
BlackRock
New York
$5.32M +$827K +178,069 +31%
Marshall Wace
7
Marshall Wace
United Kingdom
$4.27M – – –
Vanguard Group
8
Vanguard Group
Pennsylvania
$3.63M +$145K +31,208 +7%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$1.74M +$249K +53,646 +28%
State Street
10
State Street
Massachusetts
$953K – – –
DCM
11
DAFNA Capital Management
California
$939K – – –
UOC
12
UBS O'Connor
Illinois
$908K +$156K +33,506 +36%
Northern Trust
13
Northern Trust
Illinois
$770K +$128K +27,601 +34%
Renaissance Technologies
14
Renaissance Technologies
New York
$734K +$476K +102,600 New
Millennium Management
15
Millennium Management
New York
$683K +$443K +95,497 New
Charles Schwab
16
Charles Schwab
California
$553K +$41.2K +8,881 +13%
BCM
17
Bridgeway Capital Management
Texas
$416K +$122K +26,200 +82%
ETC
18
Exchange Traded Concepts
Oklahoma
$402K +$199K +42,911 +323%
BBA
19
Baker Bros. Advisors
New York
$378K +$245K +52,885 New
Bank of New York Mellon
20
Bank of New York Mellon
New York
$175K -$1.77K -382 -2%
Barclays
21
Barclays
United Kingdom
$152K -$14.7K -3,160 -13%
Morgan Stanley
22
Morgan Stanley
New York
$123K -$158K -34,019 -66%
PCM
23
Prelude Capital Management
New York
$93K +$60.3K +13,000 New
UBS Group
24
UBS Group
Switzerland
$91.1K +$59.2K +12,745 New
N
25
Nuveen
North Carolina
$84.5K – – –
1
2 3

ACRV Hedge Fund Activity: Q1 2024 in Review

48 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Acrivon Therapeutics (ACRV) for Q1 2024, worth a combined $109M — up 46% from $74.6M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ACRV positions and 6 closed out — a net gain of 6 holders — while 14 added to existing stakes and 9 trimmed.

The largest buyer was BlackRock, adding an estimated $827K. The largest seller was NEA Management Company, exiting entirely with an estimated $1.29M sold.

  • 48 institutional investors held Acrivon Therapeutics (ACRV) as of Q1 2024, up from 42 in Q4 2023.
  • Funds reported $109M of Acrivon Therapeutics stock for Q1 2024, up 46% quarter-over-quarter.
  • 12 funds opened new Acrivon Therapeutics positions in Q1 2024 and 6 closed out, a net change of +6 holders.
  • The largest Acrivon Therapeutics buyer in Q1 2024 was BlackRock, an estimated $827K added.
  • The largest Acrivon Therapeutics seller in Q1 2024 was NEA Management Company, an estimated $1.29M sold.

Based on aggregated 13F filings for Q1 2024.